ofloxacin has been researched along with Long QT Syndrome in 12 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Long QT Syndrome: A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of AT on QT interval prolongation may not have been significant at the dosage of 400 mg." | 2.94 | Relationship between antofloxacin concentration and QT prolongation and estimation of the possible false-positive rate. ( He, YC; Huang, JH; Li, LJ; Li, YF; Liang, LY; Wang, K; Xu, FY; Yang, J; Zheng, QS, 2020) |
| " Periodic and continuous ECGs were recorded before and after subjects were dosed with placebo and increasing doses of levofloxacin (500 mg, 1000 mg, 1500 mg) that included doses twice the maximum recommended dose of 750 mg in a double-blind, randomized, four-period, four-sequence crossover trial." | 2.71 | Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings. ( Chien, S; Goodman, DB; Natarajan, J; Noel, GJ; Padmanabhan, M; Solanki, B, 2004) |
| " The incidence of adverse reactions was 1." | 1.34 | Post-marketing surveillance of the safety of levofloxacin in Japan. ( Kawai, H; Komiya, M; Matsumoto, T; Nakayasu, T; Shimada, J; Yamaguchi, H; Yokoyama, H, 2007) |
| "Fluoxetine is a potent inhibitor of CYP2D6, and imipramine is metabolized by CYP2D6." | 1.33 | QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine. ( Blackmon, CL; Nykamp, DL; Roberson, AG; Schmidt, PE, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 9 (75.00) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Liang, LY | 1 |
| He, YC | 1 |
| Li, YF | 1 |
| Yang, J | 1 |
| Xu, FY | 1 |
| Li, LJ | 1 |
| Huang, JH | 1 |
| Wang, K | 1 |
| Zheng, QS | 1 |
| Zeuli, JD | 1 |
| Wilson, JW | 1 |
| Estes, LL | 1 |
| Noel, GJ | 1 |
| Goodman, DB | 1 |
| Chien, S | 1 |
| Solanki, B | 1 |
| Padmanabhan, M | 1 |
| Natarajan, J | 1 |
| Nykamp, DL | 1 |
| Blackmon, CL | 1 |
| Schmidt, PE | 1 |
| Roberson, AG | 1 |
| Wooten, JM | 1 |
| Makaryus, AN | 1 |
| Byrns, K | 1 |
| Makaryus, MN | 1 |
| Natarajan, U | 1 |
| Singer, C | 1 |
| Goldner, B | 1 |
| Tsikouris, JP | 1 |
| Peeters, MJ | 1 |
| Cox, CD | 1 |
| Meyerrose, GE | 1 |
| Seifert, CF | 1 |
| Yamaguchi, H | 1 |
| Kawai, H | 1 |
| Matsumoto, T | 1 |
| Yokoyama, H | 1 |
| Nakayasu, T | 1 |
| Komiya, M | 1 |
| Shimada, J | 1 |
| Samaha, FF | 1 |
| Chiba, K | 1 |
| Sugiyama, A | 1 |
| Satoh, Y | 1 |
| Shiina, H | 1 |
| Hashimoto, K | 1 |
| Iannini, PB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial of Tamoxifen Combined With Amphotericin B and Fluconazole for Cryptococcal Meningitis[NCT03112031] | Phase 2 | 50 participants (Actual) | Interventional | 2017-10-10 | Completed | ||
| An Open Label, Randomized Controlled Trial to Establish the Efficacy and Safety of a Study Strategy Consisting of 6 Months of Bedaquiline (BDQ), Delamanid (DLM), and Linezolid (LNZ), With Levofloxacin (LVX) and Clofazimine (CFZ) Compared to the Current So[NCT04062201] | Phase 3 | 402 participants (Actual) | Interventional | 2019-08-22 | Active, not recruiting | ||
| STREAM: The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB[NCT02409290] | Phase 3 | 588 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
probable or definite failure or recurrence (FoR) (NCT02409290)
Timeframe: final efficacy week (between 96 and 132 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 17 |
| Regimen C (Oral Regimen) | 4 |
| Regimen D (6-month Regimen) | 0 |
The proportion of patients with failure or recurrence (FoR) (NCT02409290)
Timeframe: 132 weeks, control regimen (arm B) using concurrent controls only
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen B (Control Regimen) | 14 |
| Regimen D (6-month Regimen) | 2 |
The proportion of patients with a favourable outcome at their last efficacy visit (NCT02409290)
Timeframe: Last efficacy visit, between 96 and 132 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 17 |
| Regimen B (Control Regimen) | 126 |
| Regimen C (Oral Regimen) | 152 |
| Regimen D (6-month Regimen) | 115 |
The proportion of patients with acquired drug resistance (any drug) (NCT02409290)
Timeframe: 132 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 5 |
| Regimen C (Oral Regimen) | 5 |
| Regimen D (6-month Regimen) | 3 |
The primary efficacy outcome of the STREAM Stage 2 comparison is status at Week 76 i.e. the proportion of patients with a favourable outcome at Week 76 (NCT02409290)
Timeframe: 76 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 133 |
| Regimen C (Oral Regimen) | 162 |
| Regimen D (6-month Regimen) | 122 |
3 trials available for ofloxacin and Long QT Syndrome
| Article | Year |
|---|---|
Relationship between antofloxacin concentration and QT prolongation and estimation of the possible false-positive rate.
Topics: Adult; Anti-Bacterial Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Met | 2020 |
Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Cross-Over Studies; Dizziness; Dose-Response Re | 2004 |
Effects of three fluoroquinolones on QT analysis after standard treatment courses.
Topics: Analysis of Variance; Aza Compounds; Ciprofloxacin; Cross-Over Studies; Electrocardiography; Female; | 2006 |
9 other studies available for ofloxacin and Long QT Syndrome
| Article | Year |
|---|---|
Effect of combined fluoroquinolone and azole use on QT prolongation in hematology patients.
Topics: Adult; Aged; Antifungal Agents; Drug Administration Schedule; Drug Therapy, Combination; Electrocard | 2013 |
Moxifloxacin: new preparation. A me-too with more cardiac risks.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Approval; Fluoroquinolones; France | 2002 |
QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.
Topics: Anti-Infective Agents, Urinary; Antidepressive Agents; Cytochrome P-450 CYP2D6 Inhibitors; Drug Syne | 2005 |
Drug-induced QT prolongation.
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Electrocardiography; Female; Humans; Long QT Syndrome; O | 2006 |
Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant "clinical" event?
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Electrocardiography; F | 2006 |
Post-marketing surveillance of the safety of levofloxacin in Japan.
Topics: Achilles Tendon; Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Chemical and | 2007 |
QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Electrocardiography; Female; Heart Conduction System | 1999 |
Proarrhythmic effects of fluoroquinolone antibacterial agents: in vivo effects as physiologic substrate for torsades.
Topics: Action Potentials; Animals; Anti-Infective Agents; Dogs; Electrocardiography, Ambulatory; Female; Fl | 2000 |
Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.
Topics: Amiodarone; Animals; Anti-Infective Agents; Drug Combinations; Drug Interactions; Enzyme Inhibitors; | 2001 |